Abstract
The selective toxicity of depressant scorpion neurotoxins to insects is useful in studying the insect sodium channel gating, as well as being relevant to several other applications. In order to carry out structure/activity studies, the functional expression of such polypeptides is required. In the work reported here, the cDNA of a new peptide from the venom of the scorpion Buthotus saulcyi was cloned and sequenced. It codes for a 64 residues peptide (BsaulI) with 8 highly-conserved cysteines. This peptide shares high sequence similarity with depressant insect toxins of other scorpion species. Large amounts of insoluble BsaulI protein were expressed in Escherichia coli. Purification of this peptide was carried out under denaturing conditions. Renaturation was performed by pulsed dilution of the denatured BsaulI in the refolding buffer. Production of refolded Bsaul1, however, is approximately an order of magnitude higher than that obtained with similar scorpion depressant toxins. Intrinsic fluorescence, far-UV circular dichroism spectra and biological activity assays indicate that the peptide adopts a folded structure.
Keywords: Scorpion, depressant toxin, protein expression, refolding, Buthotus saulcyi, secondary structure
Protein & Peptide Letters
Title: Efficient In Vitro Refolding and Characterization of a New Peptide from the Scorpion Buthotus saulcyi Venom Produced in Escherichia coli
Volume: 13 Issue: 7
Author(s): Maryam Nikkhah, Hossein Naderi-Manesh, Mohamad N. Sarbolouki and Bijan Ranjbar
Affiliation:
Keywords: Scorpion, depressant toxin, protein expression, refolding, Buthotus saulcyi, secondary structure
Abstract: The selective toxicity of depressant scorpion neurotoxins to insects is useful in studying the insect sodium channel gating, as well as being relevant to several other applications. In order to carry out structure/activity studies, the functional expression of such polypeptides is required. In the work reported here, the cDNA of a new peptide from the venom of the scorpion Buthotus saulcyi was cloned and sequenced. It codes for a 64 residues peptide (BsaulI) with 8 highly-conserved cysteines. This peptide shares high sequence similarity with depressant insect toxins of other scorpion species. Large amounts of insoluble BsaulI protein were expressed in Escherichia coli. Purification of this peptide was carried out under denaturing conditions. Renaturation was performed by pulsed dilution of the denatured BsaulI in the refolding buffer. Production of refolded Bsaul1, however, is approximately an order of magnitude higher than that obtained with similar scorpion depressant toxins. Intrinsic fluorescence, far-UV circular dichroism spectra and biological activity assays indicate that the peptide adopts a folded structure.
Export Options
About this article
Cite this article as:
Nikkhah Maryam, Naderi-Manesh Hossein, Sarbolouki N. Mohamad and Ranjbar Bijan, Efficient In Vitro Refolding and Characterization of a New Peptide from the Scorpion Buthotus saulcyi Venom Produced in Escherichia coli, Protein & Peptide Letters 2006; 13 (7) . https://dx.doi.org/10.2174/092986606777790557
DOI https://dx.doi.org/10.2174/092986606777790557 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognition in First-Episode Psychosis: From Phenomenology to Intervention
Current Psychiatry Reviews Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study
Current Alzheimer Research Opiate-Induced Analgesia: Contributions From Mu, Delta and Kappa Opioid Receptors Mouse Mutants
Current Pharmaceutical Design Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry Characterization of Heme Oxygenase in Adult Rodent Platelets
Current Neurovascular Research Effect of Coenzyme Q10 Supplementation on Urinary and Salivary Oxidative Stress Biomarkers in Bipolar Patients During the Depressive Episode
The Natural Products Journal The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine COMT Implication in Cognitive and Psychiatric Symptoms in Chromosome 22q11 Microdeletion Syndrome: A Selective Review
CNS & Neurological Disorders - Drug Targets P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets M1 Muscarinic Agonists Target Major Hallmarks of Alzheimers Disease – an Update
Current Alzheimer Research Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Synthesis and Characterization of New Galanthamine Derivatives Comprising Peptide Moiety
Protein & Peptide Letters The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research Genetic Enhancement in Sport: Just Another Form of Doping?
Recent Patents on DNA & Gene Sequences Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Review of Pediatric Uveitis
Current Pediatric Reviews A Spectrum of Topics for 2019: Advances in Neuroinflammation, Oxidative Stress, Obesity, Diabetes Mellitus, Cardiovascular Disease, Autism, Exosomes, and Central Nervous System Diseases
Current Pharmaceutical Design